Vital Signs — Friday, October 30, 2026

"Don't explain your philosophy. Embody it." — Epictetus, Enchiridion

A good standard for a clinic day: let the work itself show what you stand for.

Editor's Pick

  • Compressed heartworm treatment shows 95 percent efficacy — A randomized JAVMA trial in 168 shelter dogs found a two-dose melarsomine protocol (days 14 and 15) hit 95.3% efficacy versus 98.8% for the standard three-dose course, with all dogs surviving treatment. Why it matters: a shorter, cheaper protocol could let shelters treat more heartworm-positive dogs instead of leaving them waiting on cost and kennel space.

By the Numbers

  • ~2 years — the time the FDA says its new risk-based pilot could shave off the human food safety residue evaluation for new animal drugs. Takeaway: food-animal drug approvals may speed up noticeably, which eventually means more treatment options reaching mixed and large-animal practices sooner.

In the Journals

AI Watch

The Business End

  • Feline vet visits rise as puppy visits decline, data show — Cat visits rose 2.7% year over year in Q3 2026 while dog visits fell 3.3%, with cats now 24% of companion-animal visits and puppy visits tracking 44% below the pre-pandemic baseline, making feline retention a strategic priority rather than a side project.
  • Clinical research at any scale: Finding your fit — Taking part in clinical studies, even just by flagging trials to clients or collecting samples, can build loyalty, energize the team, and add billable work, with trial-site status as the deeper option for practices with the caseload to support it.
  • ELEVATE: The Veterinary Technician Leadership Academy — A new six-month leadership academy for early-career veterinary technicians (cohort of twelve, January kickoff to July graduation) is taking applications through November 13, a retention-friendly development opportunity worth passing along to a promising tech.

The Fine Print

The Feel-Good Finish

Know an independent practice owner? Forward this.

Read more

© 2026 Vital Signs. Forwarding to a colleague is welcome; please don't republish without permission.